479 related articles for article (PubMed ID: 18323549)
1. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.
Fournier A; Fabre A; Mesrine S; Boutron-Ruault MC; Berrino F; Clavel-Chapelon F
J Clin Oncol; 2008 Mar; 26(8):1260-8. PubMed ID: 18323549
[TBL] [Abstract][Full Text] [Related]
2. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.
Li CI; Malone KE; Porter PL; Weiss NS; Tang MT; Cushing-Haugen KL; Daling JR
JAMA; 2003 Jun; 289(24):3254-63. PubMed ID: 12824206
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
[TBL] [Abstract][Full Text] [Related]
4. Progestagens use before menopause and breast cancer risk according to histology and hormone receptors.
Fabre A; Fournier A; Mesrine S; Gompel A; Desreux J; Berrino F; Boutron-Ruault MC; Romieu I; Clavel-Chapelon F
Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2723-8. PubMed ID: 18843015
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
Kinsella MD; Nassar A; Siddiqui MT; Cohen C
Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
[TBL] [Abstract][Full Text] [Related]
6. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study.
Bardia A; Olson JE; Vachon CM; Lazovich D; Vierkant RA; Wang AH; Limburg PJ; Anderson KE; Cerhan JR
Breast Cancer Res Treat; 2011 Feb; 126(1):149-55. PubMed ID: 20669045
[TBL] [Abstract][Full Text] [Related]
7. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.
Fournier A; Berrino F; Clavel-Chapelon F
Breast Cancer Res Treat; 2008 Jan; 107(1):103-11. PubMed ID: 17333341
[TBL] [Abstract][Full Text] [Related]
8. Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age.
Li CI; Daling JR; Haugen KL; Tang MT; Porter PL; Malone KE
Breast Cancer Res Treat; 2014 Jun; 145(2):481-9. PubMed ID: 24748570
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
10. Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: A prospective cohort study.
Suzuki R; Rylander-Rudqvist T; Ye W; Saji S; Wolk A
Int J Cancer; 2006 Oct; 119(7):1683-9. PubMed ID: 16646051
[TBL] [Abstract][Full Text] [Related]
11. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
[TBL] [Abstract][Full Text] [Related]
12. Expression of estrogen and progesterone receptors in human ductal invasive breast carcinoma not otherwise specified: is there any difference between premenopausal and postmenopausal women?
Petricević J; Petković M; Jonjić N
Acta Clin Croat; 2011 Jun; 50(2):169-75. PubMed ID: 22263379
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
14. Dietary fiber intake and risk of postmenopausal breast cancer defined by estrogen and progesterone receptor status--a prospective cohort study among Swedish women.
Suzuki R; Rylander-Rudqvist T; Ye W; Saji S; Adlercreutz H; Wolk A
Int J Cancer; 2008 Jan; 122(2):403-12. PubMed ID: 17764112
[TBL] [Abstract][Full Text] [Related]
15. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Prat A; Saura C; Pascual T; Hernando C; Muñoz M; Paré L; González Farré B; Fernández PL; Galván P; Chic N; González Farré X; Oliveira M; Gil-Gil M; Arumi M; Ferrer N; Montaño A; Izarzugaza Y; Llombart-Cussac A; Bratos R; González Santiago S; Martínez E; Hoyos S; Rojas B; Virizuela JA; Ortega V; López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J
Lancet Oncol; 2020 Jan; 21(1):33-43. PubMed ID: 31838010
[TBL] [Abstract][Full Text] [Related]
16. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
[TBL] [Abstract][Full Text] [Related]
17. The estrogen receptor negative-progesterone receptor positive breast carcinoma is a biological entity and not a technical artifact.
Ng CH; Pathy NB; Taib NA; Mun KS; Rhodes A; Yip CH
Asian Pac J Cancer Prev; 2012; 13(4):1111-3. PubMed ID: 22799290
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
Khabaz MN
Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
[TBL] [Abstract][Full Text] [Related]
19. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]